Compare RHI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | CELC |
|---|---|---|
| Founded | 1948 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.2B |
| IPO Year | 1994 | 2017 |
| Metric | RHI | CELC |
|---|---|---|
| Price | $41.90 | $64.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $39.56 | ★ $150.85 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $5,378,506,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | $1,921.71 |
| P/E Ratio | $46.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.83 | $53.54 |
| 52 Week High | $47.14 | $151.02 |
| Indicator | RHI | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 42.83 |
| Support Level | $35.08 | $53.54 |
| Resistance Level | $42.25 | $73.29 |
| Average True Range (ATR) | 1.58 | 4.12 |
| MACD | -0.19 | 0.27 |
| Stochastic Oscillator | 17.03 | 25.58 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.